Moyom Secures EU MDR Certification for APHRANEL®, Forms Scientific Collaboration
Biotechnology company MOYOM has achieved European Medical Device Regulation (EU MDR) certification for its APHRANEL® product. The company has also established a strategic scientific collaboration with Expert2Expert.
LONDON – Biotechnology firm MOYOM has reached a significant milestone in its European strategy by successfully obtaining European Medical Device Regulation (EU MDR) certification for its APHRANEL® product.
The certification is crucial for MOYOM's continued advancement in the regenerative aesthetics sector across Europe. Alongside this regulatory achievement, the company announced the establishment of a strategic scientific collaboration with Expert2Expert. This partnership aims to further research and development in regenerative aesthetics within continental Europe.
MOYOM is a biotechnology company focused on the field of regenerative aesthetics, with APHRANEL® being its key product in this area. The collaboration with Expert2Expert, a network of scientific specialists, is expected to drive innovation and clinical progress.
These developments strengthen MOYOM's market presence in Europe and underscore its commitment to adhering to stringent regulatory standards and fostering scientific advancement within the industry.